. Drug repurposing for venetoclax-resistant acute myeloid leukemia.
| LADUNGOVÁ, Adriana, Daniel BUŠA, Yusuf LODHI, Jan HÝL, Martin ČULEN and Michal ŠMÍDA. . Drug repurposing for venetoclax-resistant acute myeloid leukemia. In PhD retreat 2022, Telč. 2022. |
|
Other formats:
BibTeX
LaTeX
RIS
|
| Basic information | |
|---|---|
| Original name | . Drug repurposing for venetoclax-resistant acute myeloid leukemia. |
| Authors | LADUNGOVÁ, Adriana, Daniel BUŠA, Yusuf LODHI, Jan HÝL, Martin ČULEN and Michal ŠMÍDA. |
| Edition | PhD retreat 2022, Telč, 2022. |
| Other information | |
|---|---|
| Type of outcome | Conference abstract |
| Confidentiality degree | is not subject to a state or trade secret |
| Organization unit | Central European Institute of Technology |
| Tags | NÚVR_CEITEC |
| Changed by | Changed by: Bc. Kateřina Kolesová, učo 112275. Changed: 20/1/2023 15:09. |
| Links | |
|---|---|
| LX22NPO5102, research and development project | Name: Národní ústav pro výzkum rakoviny (Acronym: NÚVR) |
| Investor: Ministry of Education, Youth and Sports of the CR, National institute for cancer research, 5.1 EXCELES | |
| MUNI/A/1330/2021, interní kód MU | Name: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit IX (Acronym: VýDiTeHeMa IX) |
| Investor: Masaryk University | |
| MUNI/A/1419/2021, interní kód MU | Name: Specifický výzkum v oblasti „Life Sciences“ |
| Investor: Masaryk University | |
PrintDisplayed: 28/8/2024 15:30